Literature DB >> 19880184

The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy.

Ronald Klein1, Kristine E Lee, Ronald E Gangnon, Barbara E K Klein.   

Abstract

OBJECTIVE: To examine the 25-year cumulative incidence of visual impairment (VI) and its relation to various risk factors.
DESIGN: Population-based study. PARTICIPANTS: Nine hundred fifty-five insulin-taking persons living in an 11-county area in southern Wisconsin with type 1 diabetes diagnosed before age 30 years who participated in a baseline (1980-1982) and at least 1 of 4 follow-up (4-, 10-, 14-, and 25-year) examinations or who died before the first follow-up examination (n = 64).
METHODS: Best-corrected visual acuity (VA) was measured using a modification of the Early Treatment Diabetic Retinopathy Study protocol. Visual impairment and severe VI were defined as best-corrected VA in the better eye of 20/40 or worse and 20/200 or worse, respectively. MAIN OUTCOME MEASURES: Incidence of VI.
RESULTS: The 25-year cumulative incidences of any VI and severe VI (accounting for competing risk of death) were 13% and 3%, respectively. Multivariate models showed increased risk of VI was associated (hazard ratio, 95% confidence interval, and P value) with more severe baseline retinopathy (1.14 per 1-step increase in retinopathy level; 1.03-1.27; P = 0.01), presence of cataract (2.49 versus absence; 1.53-4.04; P<0.001), higher glycosylated hemoglobin (1.28 per 1%; 1.16-1.42; P<0.001), presence of hypertension (1.72 versus absence; 1.05-2.83; P = 0.03), and currently smoking (vs. never smoked, 1.63; 1.01-2.61; P = 0.04), but not proteinuria.
CONCLUSIONS: These data show that the 25-year cumulative incidence of VI is related to modifiable risk factors and, therefore, that VI may be reduced by better glycemic and blood pressure control and avoidance of smoking. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19880184      PMCID: PMC2814955          DOI: 10.1016/j.ophtha.2009.06.051

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  38 in total

1.  Diabetic retinopathy, visual acuity, and medical risk indicators: a continuous 10-year follow-up study in Type 1 diabetic patients under routine care.

Authors:  M Lövestam-Adrian; C D Agardh; O Torffvit; E Agardh
Journal:  J Diabetes Complications       Date:  2001 Nov-Dec       Impact factor: 2.852

2.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.

Authors:  Robert W Schrier; Raymond O Estacio; Anne Esler; Philip Mehler
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

3.  Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study.

Authors:  H Buch; T Vinding; N V Nielsen
Journal:  Ophthalmology       Date:  2001-12       Impact factor: 12.079

4.  Occurrence and predictors of retinopathy and visual acuity in Type 2 diabetic patients and control subjects. 10-year follow-up from the diagnosis.

Authors:  R M Voutilainen-Kaunisto; M E Teräsvirta; M I Uusitupa; L K Niskanen
Journal:  J Diabetes Complications       Date:  2001 Jan-Feb       Impact factor: 2.852

5.  The incidence of visual impairment due to diabetic retinopathy in Leeds.

Authors:  N Kumar; E Goyder; M McKibbin
Journal:  Eye (Lond)       Date:  2006-04       Impact factor: 3.775

6.  Association of ocular disease and mortality in a diabetic population.

Authors:  R Klein; B E Klein; S E Moss; K J Cruickshanks
Journal:  Arch Ophthalmol       Date:  1999-11

7.  Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.

Authors:  David R Matthews; Irene M Stratton; Stephen J Aldington; Rury R Holman; Eva M Kohner
Journal:  Arch Ophthalmol       Date:  2004-11

8.  The incidence of visual impairment and its determinants in the WHO Multinational Study of Vascular Disease in Diabetes.

Authors:  E Miki; M Lu; E T Lee; H Keen; P H Bennett; D Russell
Journal:  Diabetologia       Date:  2001-09       Impact factor: 10.122

9.  Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.

Authors:  Anne Katrin Sjølie; Ronald Klein; Massimo Porta; Trevor Orchard; John Fuller; Hans Henrik Parving; Rudy Bilous; Nish Chaturvedi
Journal:  Lancet       Date:  2008-09-25       Impact factor: 79.321

10.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes.

Authors:  Ronald Klein; Michael D Knudtson; Kristine E Lee; Ronald Gangnon; Barbara E K Klein
Journal:  Ophthalmology       Date:  2008-11       Impact factor: 12.079

View more
  58 in total

Review 1.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

Authors:  J G Garweg; A Wenzel
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

Review 2.  Future opportunities in diabetic retinopathy research.

Authors:  Thomas W Gardner; Emily Y Chew
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-04       Impact factor: 3.243

Review 3.  Research Progress in MRI of the Visual Pathway in Diabetic Retinopathy.

Authors:  Yu-Min Li; Hong-Mei Zhou; Xiang-Yang Xu; He-Shui Shi
Journal:  Curr Med Sci       Date:  2018-12-07

Review 4.  Global trends in diabetes complications: a review of current evidence.

Authors:  Jessica L Harding; Meda E Pavkov; Dianna J Magliano; Jonathan E Shaw; Edward W Gregg
Journal:  Diabetologia       Date:  2018-08-31       Impact factor: 10.122

5.  Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States.

Authors:  Neil M Bressler; Rohit Varma; Quan V Doan; Michelle Gleeson; Mark Danese; Julie K Bower; Elizabeth Selvin; Chantal Dolan; Jennifer Fine; Shoshana Colman; Adam Turpcu
Journal:  JAMA Ophthalmol       Date:  2014-02       Impact factor: 7.389

6.  Comprehensive Review of the Effects of Diabetes on Ocular Health.

Authors:  Kathryn Skarbez; Yos Priestley; Marcia Hoepf; Steven B Koevary
Journal:  Expert Rev Ophthalmol       Date:  2010-08-01

7.  Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial Cells: Potential Targets for New Biologic Drugs.

Authors:  Justine R Smith; Larry L David; Binoy Appukuttan; Phillip A Wilmarth
Journal:  Am J Ophthalmol       Date:  2018-03-17       Impact factor: 5.258

Review 8.  Fenofibrate and Diabetic Retinopathy.

Authors:  Jared E Knickelbein; Akshar B Abbott; Emily Y Chew
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

9.  Are individuals with diabetes seeing better?: a long-term epidemiological perspective.

Authors:  Ronald Klein; Barbara E K Klein
Journal:  Diabetes       Date:  2010-08       Impact factor: 9.461

10.  Inhibition of β-elemene on the expressions of HIF-lα, VEGF and iNOS in diabetic rats model.

Authors:  Yun Zhou; Yan Liu; Jun Chen; Yi-Zhou Sun; Li-Hua Li; Lei Chen
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.